Pacific Biosciences Of California (PACB) Short term Debt (2010 - 2023)

Pacific Biosciences Of California's Short term Debt history runs 6 years deep, the most recent figure standing at $96.2 million for Q3 2023.

• In Q3 2023, Short term Debt changed N/A year-over-year to $96.2 million; the TTM figure through Sep 2023 stood at $96.2 million (changed N/A YoY), while the FY2022 annual figure was $172.1 million, up 10602.36% from the prior year.
• Short term Debt was $96.2 million for Q3 2023 at Pacific Biosciences Of California, down from $186.3 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $186.3 million in Q2 2023 to a low of $1.6 million in Q4 2021.
• Historically, Short term Debt has averaged $128.1 million across 3 years, with a median of $172.1 million in 2022.
• Biggest YoY gain for Short term Debt was 10602.36% in 2022; the steepest drop was 10602.36% in 2022.
• A 3-year view of Short term Debt shows it stood at $1.6 million in 2021, then jumped by 10602.36% to $172.1 million in 2022, then plunged by 44.1% to $96.2 million in 2023.
• The last three Short term Debt figures came in at $96.2 million (Q3 2023), $186.3 million (Q2 2023), and $184.4 million (Q1 2023), per Business Quant data.